Navigation Links
Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
Date:10/23/2008

ess of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Dendreon Reports First Quarter 2008 Financial Results
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Announces Closing of Registered Direct Offering
7. Dendreon Announces $47 Million Registered Direct Offering
8. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
9. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
10. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
11. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) ... Chief Financial Officer has resigned.  The Company has hired ... who retired in December 2014, as full time interim ... successor.     Andy Ashworth began his ... a smooth transition.  Andy was the Company,s CFO from ...
(Date:7/29/2015)... ... July 29, 2015 , ... Brady (NYSE:BRC), a ... Label Guide . To align chemical container labeling with OSHA’s updated Hazard Communication ... label components, an example of an accurate label, and pictogram uses and meanings. ...
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation Impact ... products , in particular, drug/device combinations. The current system received a score of 0 ... for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... introduces CHRONO NIGHT Express Contouring Bi-Gel, a nighttime-specific product that targets fat cells ... sugars that are able to enter fat cells, inhibiting the formation of new ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Brady Announces a New GHS Label Guide 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3
... to Present at BioCentury,s Newsmakers in the Biotech,Industry, Bank of America ... ... Conferences, SEATTLE, Sept. 4 Trubion Pharmaceuticals,Inc. ... executive officer, and chairman of Trubion, will present an overview,of the ...
... Oriental,Bioengineering, Inc. (NYSE: AOB ), a leading manufacturer ... today,announced that the Company will attend the Credit Suisse ... in Shenzhen, China as well as,the 3rd Semi-Annual Investor ... Co. on September 11, 2007 in Beijing, China. ...
... entire,new industry for North Carolina is the long-term ... Carolina, which moved to reality today,following its first ... $5 million initial appropriation from the 2007 General,Assembly, ... North,Carolina,s Strategic Plan for Biofuels Leadership. The Plan ...
Cached Biology Technology:Trubion Pharmaceuticals to Present at Upcoming Investor Conferences 2American Oriental Bioengineering Announces Participation in September Investor Conferences 2N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation 2N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation 3
(Date:7/7/2015)... VIEW, Calif. , July 7, 2015 /PRNewswire/ ... biometrics market, Frost & Sullivan recognizes Credence ID, ... Sullivan Entrepreneurial Company of the Year Award. ... suite to aid in its mission of offering ... under-recognized populations globally. As Credence ID was formed ...
(Date:6/30/2015)... -- To bolster its efforts and commitment to fighting cyber ... addition of two new team members. ... David Raviv will act as head of strategic alliances. ... providing the most secure solutions for the enterprise market. ... Technologies, a provider of security and management products, which was ...
(Date:6/25/2015)... , June 25, 2015  Imagine a tool ... toward a healthier, happier life. That,s exactly what USANA,s ... to do. The cutting-edge, portable health program provides a ... solutions to help improve your lifestyle and nutrition. ... dinner and gala Wednesday night, USANA,s THA was honored ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... MADISON, WI, SEPTEMBER 28, 2009 -- Emphasizing cross-disciplinary ... mass-volume relationships, can help undergraduates learn real-world, problem-solving ... soil science careers. Drs. Josh Heitman and ... Department, highlighted this need for quantitative measurement skills ...
... A group led by Dr. Michael Teitell at UCLA ... to B-cell lymphoma development. Their report can be found ... of Pathology . B-cell lymphomas are the ... as DNA hypermethylation, may promote B-cell transformation by silencing tumor ...
... have discovered a plant in Erie County that has never ... was identified with the aid of a Mercyhurst College professor ... scouring rush is known to exist in northern U.S. states ... in Pennsylvania until this discovery. WPC scientists found a small ...
Cached Biology News:Help students think like soil scientists 2Help students think like soil scientists 3Tips from the American Journal of Pathology 2Tips from the American Journal of Pathology 3Tips from the American Journal of Pathology 4Tips from the American Journal of Pathology 5Erie County home to plant never before recorded in Pa. 2
... provide automated, higher throughput screening of 96-well ... This flexible sample format makes the Guava ... research, target validation, assay development, and even ... Guava PCA-96 uses a green laser detection ...
... delivers a novel procedure for the uniform ... whole genome DNA from small samples. This ... quick and highly reproducible amplification and labeling ... a REPLI-g Mini Kit module (QIAGEN) and ...
... The Cellomics KineticScan™ Reader is ... "Smart Solutions for Cell-based Screening". ... the ability to do both ... of physiological processes, dynamic distribution ...
... Introduction of a protein into cells permits ... signaling pathways, apoptotic pathways, and transcription factor-mediated ... studying the effects of a specific protein ... the protein directly into the cell. ProteoJuice ...
Biology Products: